Bank Of Montreal Arrowhead Pharmaceuticals, Inc. Transaction History

Bank Of Montreal

$191 Billion
Q1 2024

A detailed history of Bank Of Montreal transactions in Arrowhead Pharmaceuticals, Inc. stock. As of the latest transaction made, Bank Of Montreal holds 12,833 shares of ARWR stock, worth $328,139. This represents 0.0% of its overall portfolio holdings.

Number of Shares

12,833

Previous 11,885 7.98%

Holding current value

$328,139

Previous $363,000 1.1%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 13, 2024	BUY	$27.21 - $39.48 $25,795 - $37,427	948 Added 7.98%	12,833 $367,000
Q4 2023 Feb 08, 2024	BUY	$21.2 - $31.03 $30,570 - $44,745	1,442 Added 13.81%	11,885 $363,000
Q3 2023 Nov 01, 2023	SELL	$26.2 - $36.08 $7,309 - $10,066	-279 Reduced 2.6%	10,443 $280,000
Q2 2023 Aug 02, 2023	SELL	$25.16 - $41.38 $128,039 - $210,582	-5,089 Reduced 32.19%	10,722 $382,000
Q1 2023 Jun 13, 2024	BUY	$23.68 - $38.51 $142,435 - $231,637	6,015 Added 46.87%	18,848 $478,000

Q4 2022 Feb 01, 2023	BUY	$28.0 - $40.56 $79,016 - $114,460	2,822 Added 21.73%	15,811 $641,000
Q3 2022 Nov 10, 2022	BUY	$29.63 - $48.31 $58,726 - $95,750	1,982 Added 18.01%	12,989 $536,000
Q2 2022 Aug 11, 2022	BUY	$27.79 - $50.61 $47,715 - $86,897	1,717 Added 18.48%	11,007 $372,000
Q1 2022 May 12, 2022	SELL	$39.62 - $69.97 $82,568 - $145,817	-2,084 Reduced 18.32%	9,290 $423,000
Q4 2021 Feb 11, 2022	BUY	$58.09 - $82.51 $54,546 - $77,476	939 Added 9.0%	11,374 $780,000
Q3 2021 Nov 12, 2021	SELL	$58.38 - $84.96 $27,613 - $40,186	-473 Reduced 4.34%	10,435 $643,000
Q2 2021 Aug 12, 2021	BUY	$62.15 - $90.32 $677,932 - $985,210	10,908 New	10,908 $903,000

Others Institutions Holding ARWR

# of Institutions

296

Shares Held

88.5M

Call Options Held

905K

Put Options Held

387K

View Full List

About ARROWHEAD PHARMACEUTICALS, INC.

Ticker ARWR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 105,849,000
Market Cap $2.71B
Description
Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in Phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, w...

More about ARWR

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Bank Of Montreal , based on Form 13F filings with the SEC.

News

Stay updated on Bank Of Montreal with notifications on news.

Account